This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Arrowhead Presents Data On DPC System At TIDES 2012

Stocks in this article: ARWR

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that Darren Wakefield, Ph.D., one of its Senior Scientists at its Madison, WI research and development facility presented data at the TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Las Vegas, NV. Dr. Wakefield’s poster presentation titled, “Liver-targeted and reversibly masked-polycation co-delivery improves cholesterol-conjugated siRNA efficacy,” describes the ability of Arrowhead’s PBAVE polymer to dramatically decrease the effective dose needed. PBAVE is one of the polymers included in Arrowhead’s proprietary Dynamic Polyconjugate (DPC) siRNA delivery platform.

“Linkage to cholesterol is one strategy that has been used by other siRNA therapeutic developers to prolong circulation time and to facilitate uptake into hepatocytes via the LDL receptor,” said Dr. Wakefield. “However, three daily injections of 50 mg/kg of cholesterol-conjugated apoB siRNA were previously required to achieve 50% gene silencing. Over the past few years, no real improvements have been reported to optimize the delivery of cholesterol or other lipophilic siRNA conjugates in vivo. Using our delivery technology, we are able to achieve similar gene silencing with a dramatically lower dose. This demonstration is one example of the potential of our DPC platform to broaden the utility and safety of siRNA therapeutics.”

Arrowhead’s chemists employed a new delivery approach to achieve similar gene silencing after a single injection of 0.2 mg/kg of cholesterol-conjugated siRNA, a 750-fold improvement in effective dose. This enhanced efficacy is attained by the co-delivery of an asiologlycoprotein receptor (ASGPr)-targeted and reversibly-masked cationic polymer, PBAVE. The injection of cholesterol-conjugated siRNA and modified-polymer can be temporally separated up to four hours without significant effects on gene silencing, suggesting that delivery does not depend on the association of targeted PBAVE and the cholesterol-conjugated siRNA in the blood. Genetic knockout of the ASGPr eliminates effective delivery of the cholesterol-conjugated siRNA, indicating that delivery depends on proper targeting of the PBAVE polymer.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs